Gadolinium-based contrast agents (GBCAs) have traditionally been considered very safe. The incidence of life-threatening adverse reactions occurring within 24 hours of GBCA administration is extremely low. Nephrogenic systemic fibrosis, a rare clinical entity first described in 2006, has essentially been eradicated given changes in practice in the use of GBCAs in patients with renal insufficiency. … more »